Another promising therapy Gliovac trial for rGBM:(recurrent)
Gliovac trial sounds promising for rGBM:
"Principal investigator of the clinical trial, Daniela Bota, MD, PhD, commented, “Prior to this study of ERC1671 immunotherapy for recurrent GBM, it was almost unknown for such patients to experience recovery. We are excited to accelerate recruitment and complete this study.” Dr. Bota is Vice Dean for Clinical Research, Medical Director, UCI Center for Clinical Research; Director, UCI Alpha Stem Cell Clinic; Medical Director, UCI Health Comprehensive Brain Tumor Program.
Apostolos Stathopoulos, MD, PhD, President and CEO of ERC Worldwide commented, “We are encouraged by such strong results for ERC1671 in Dr. Bota’s study and pleased to see a high number of patients going into remission. We believe that ERC1671 is finally leading the way for immunotherapy to treat intractable cancers like recurrent GBM that currently do not have alternative therapeutic options.”
Comments
Post a Comment